Atossa Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the stock and has a $7.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Emily Bodnar’s rating is based on several promising developments regarding Atossa Therapeutics’ clinical program for Z-endoxifen. The company has received positive feedback from the FDA, which has clarified the regulatory pathway for their Phase 2/3 dose optimization trial in patients with ER+/HER2- metastatic breast cancer. This feedback, which was provided in writing instead of a virtual meeting, suggests the FDA’s agreement with Atossa’s proposed plans, thereby validating key components of their clinical development strategy.
Furthermore, the FDA has deemed Atossa’s nonclinical safety data and cardiac safety assessment plan as adequate, indicating no need for additional toxicity studies. The anticipated trial will explore Z-endoxifen both as a monotherapy and in combination with standard-of-care therapies, with a focus on optimizing dosage levels. The company’s commitment to submitting an IND by the fourth quarter of 2025 and potentially starting patient dosing in early 2026 reflects a proactive approach, reinforcing the positive outlook for Atossa’s stock.
According to TipRanks, Bodnar is an analyst with an average return of -0.6% and a 32.60% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Agenus, NovoCure, and Jasper Therapeutics.